| Catalog_no |
ADMC0635 |
| Product_name |
MK-5172 |
| Category |
抑制剂与激动剂 |
| Size |
10mg/50mg/100mg |
| Price |
1560.00/5000.00/7220.00 |
| Specificity |
Target: HCV Protease. Fields: MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. Ki: 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a |
| Dilution |
Ki: 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a)[1] |
| Purification |
>98% |
| Concentration |
靶点：HCV Protease;IC50：Ki: 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a)[1] |
| Storage_stability |
2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
| othername |
MK 5172; MK5172 |
| Molecular Weight |
766.9 |
| Notes |
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. Ki: 0.01±<0.01 nM (gt1b), 0.01±0.01 nM (gt1a), 0.08±0.02 nM (gt2a), 0.15±0.06 nM (gt2b), 0.90±0.2 nM (gt3a)[1] |
| Instructions |
 查看与下载 |
